Skip to main content
  • Clinical
      |Clinical
    • Acute Coronary Syndromes
    • Cardiac Surgery
    • Covid-19
    • Heart Failure
    • Heart Health
    • Heart Rhythm
    • Hypertension
    • Interventional Cardiology
    • Mitral Valve
    • Pharmaceutics
    • Structural Heart Disease
    • TAVR
    • Tricuspid Valve
    • Vascular & Endovascular
  • Management
      |Management
    • Chest Pain Guidelines
    • Compensation
    • Economics
    • Education & Training
    • Legal News
    • Patient Care
    • Policy & Regulations
    • Professional Associations
    • Quality
    • Revenue
    • Staffing
  • Technology
      |Technology
    • AI
    • Cardiac Imaging
    • Cath Lab
    • CT
    • CVIS
    • ECG
    • Echo
    • EP Lab
    • Informatics
    • MRI
    • Nuclear Cardiology
    • Remote Monitoring
  • Videos
  • Conferences
      |Conferences
    • ACC
    • AHA
    • ASE
    • ASNC
    • ESC
    • EuroPCR
    • HFSA
    • HRS
    • HRS
    • SCAI
    • SCCT
    • SIIM
    • SNMMI
    • STS
    • TCT
    • VIVA
  • Custom Content
      |Custom Content
    • Experience Stories
    • Webinars & Videos
  • Subscribe
  • Forty Under 40 Award
      |Forty Under 40 Award
    • Class of 2026
    • Class of 2025

Search form

Home

News You Need to Know Today
SCAI's new president outlines his goals | Tirzepatide wins battle of the diabetes drugs | AI predicts LBBB risk in TAVR patients
Tuesday, May 6, 2025
Link to Twitter Link to Facebook Link to Linkedin Link to Vimeo

Today's News and Trends

New SCAI president lists advocacy, cardiogenic shock among his top priorities

Srihari Naidu, MD, spoke to Cardiovascular Business about his plan to take SCAI in some bold new directions.

READ MORE >
Srihari S. Naidu, MD, FACC, FAHA, MSCAI, assumed the role of president of the Society for Cardiovascular Angiography and Interventions (SCAI) May 3 during the society's annual meeting. He outlined his ambitious plans to take SCAI in some new directions. #SCAI #SCAI2025
Share on Twitter Share on Facebook Share on Linkedin

New SCAI president lists advocacy, cardiogenic shock among his top priorities

Share on Twitter Share on Facebook Share on Linkedin
Srihari S. Naidu, MD, FACC, FAHA, MSCAI, assumed the role of president of the Society for Cardiovascular Angiography and Interventions (SCAI) May 3 during the society's annual meeting. He outlined his ambitious plans to take SCAI in some new directions. #SCAI #SCAI2025
Srihari Naidu, MD, spoke to Cardiovascular Business about his plan to take SCAI in some bold new directions.
READ MORE >

Tirzepatide bests semaglutide in patients with type 2 diabetes, kidney disease and heart failure

Researchers examined data from more than 9,000 patients, sharing their findings at SCAI 2025.

READ MORE >
tirzepatide injections Zepbound Eli Lilly. The U.S. Food and Drug Administration (FDA) cleared Eli Lilly and Company’s tirzepatide injections for chronic weight management in adult patients who are obese, overweight or present with at least one weight-related condition such as high blood pressure or high cholesterol. These weekly injections are being sold and distributed under the brand name Zepbound. Tirzepatide is also used in Mounjaro, FDA cleared in 2022 for improving glycemic control in adults.
Share on Twitter Share on Facebook Share on Linkedin

Tirzepatide bests semaglutide in patients with type 2 diabetes, kidney disease and heart failure

Share on Twitter Share on Facebook Share on Linkedin
tirzepatide injections Zepbound Eli Lilly. The U.S. Food and Drug Administration (FDA) cleared Eli Lilly and Company’s tirzepatide injections for chronic weight management in adult patients who are obese, overweight or present with at least one weight-related condition such as high blood pressure or high cholesterol. These weekly injections are being sold and distributed under the brand name Zepbound. Tirzepatide is also used in Mounjaro, FDA cleared in 2022 for improving glycemic control in adults.
Researchers examined data from more than 9,000 patients, sharing their findings at SCAI 2025.
READ MORE >

AI predicts LBBB risk in TAVR patients prior to treatment

The authors tested out a variety of machine learning techniques, including large language models and more traditional algorithms. They focused on data that can be gathered prior to treatment, ensuring cardiologists know as much as possible before the procedure.

READ MORE >
artificial intelligence heart AI
Share on Twitter Share on Facebook Share on Linkedin

AI predicts LBBB risk in TAVR patients prior to treatment

Share on Twitter Share on Facebook Share on Linkedin
artificial intelligence heart AI
The authors tested out a variety of machine learning techniques, including large language models and more traditional algorithms. They focused on data that can be gathered prior to treatment, ensuring cardiologists know as much as possible before the procedure.
READ MORE >

Featured Articles

A super alternative: BATMAN helps cardiologists limit complications during TMVR

The BATMAN technique is a safe, effective way to prevent LVOT obstruction during high-risk transcatheter mitral valve replacement, according to new data presented at SCAI 2025.

READ MORE >
BATMAN LVOT
Share on Twitter Share on Facebook Share on Linkedin

A super alternative: BATMAN helps cardiologists limit complications during TMVR

Share on Twitter Share on Facebook Share on Linkedin
BATMAN LVOT
The BATMAN technique is a safe, effective way to prevent LVOT obstruction during high-risk transcatheter mitral valve replacement, according to new data presented at SCAI 2025.
READ MORE >

Consistent cannabis use linked to multiple cardiovascular risks for heart failure patients

Cannabis use can be especially harmful for heart failure patients, according to new data presented at SCAI 2025.

READ MORE >
cannabis use disorder marijuana joint weed smoking
Share on Twitter Share on Facebook Share on Linkedin

Consistent cannabis use linked to multiple cardiovascular risks for heart failure patients

Share on Twitter Share on Facebook Share on Linkedin
cannabis use disorder marijuana joint weed smoking
Cannabis use can be especially harmful for heart failure patients, according to new data presented at SCAI 2025.
READ MORE >

Nonprofit group helps doctors and startups bring new cardiovascular tech to market

Nabil Dib, MD, founder of the International Society for Cardiovascular Translational Research, details resources to help doctors and startups navigate the shift from conducting research to commercializing new products and applications.

READ MORE >
Nabil Dib, MD, director clinical and translational research, Dignity Health, and founder of the non-profit International Society for Cardiovascular Translational Research (ISCTR), explains resources ISCTR has to help doctors and start ups navigate regulatory pathways to expedite moving from research to clinical application.
Share on Twitter Share on Facebook Share on Linkedin

Nonprofit group helps doctors and startups bring new cardiovascular tech to market

Share on Twitter Share on Facebook Share on Linkedin
Nabil Dib, MD, director clinical and translational research, Dignity Health, and founder of the non-profit International Society for Cardiovascular Translational Research (ISCTR), explains resources ISCTR has to help doctors and start ups navigate regulatory pathways to expedite moving from research to clinical application.
Nabil Dib, MD, founder of the International Society for Cardiovascular Translational Research, details resources to help doctors and startups navigate the shift from conducting research to commercializing new products and applications.
READ MORE >

‘A defining moment’: How cardiologists can get the most out of CT-guided PCI

SCAI and SCCT have collaborated on a new document designed to get more interventional cardiologists to embrace CT-guided PCI going forward. 

READ MORE >
Carlos Collet, MD, PhD, (center) and colleagues perform CT-guided PCI. Image courtesy of CoreAalst.
Share on Twitter Share on Facebook Share on Linkedin

‘A defining moment’: How cardiologists can get the most out of CT-guided PCI

Share on Twitter Share on Facebook Share on Linkedin
Carlos Collet, MD, PhD, (center) and colleagues perform CT-guided PCI. Image courtesy of CoreAalst.
SCAI and SCCT have collaborated on a new document designed to get more interventional cardiologists to embrace CT-guided PCI going forward. 
READ MORE >

In Case You Missed It

Tracking major trends and clinical research in acute coronary syndrome care

Deepak Bhatt, MD, detailed several recent clinical trials that could reshape the way clinicians manage acute coronary syndrome (ACS) patients.

READ MORE >
Deepak L. Bhatt, MD, MPH, MBA, Director of Mount Sinai Fuster Heart Hospital and the Dr. Valentin Fuster Professor of Cardiovascular Medicine at the Icahn School of Medicine at Mount Sinai, explains what he sees as the top recent trials impacting acute coronary syndrome care (ACS).
Share on Twitter Share on Facebook Share on Linkedin

Tracking major trends and clinical research in acute coronary syndrome care

Share on Twitter Share on Facebook Share on Linkedin
Deepak L. Bhatt, MD, MPH, MBA, Director of Mount Sinai Fuster Heart Hospital and the Dr. Valentin Fuster Professor of Cardiovascular Medicine at the Icahn School of Medicine at Mount Sinai, explains what he sees as the top recent trials impacting acute coronary syndrome care (ACS).
Deepak Bhatt, MD, detailed several recent clinical trials that could reshape the way clinicians manage acute coronary syndrome (ACS) patients.
READ MORE >

Myval TAVR valve non-inferior to Sapien 3 after 1 year—pacemaker implants the biggest difference

India-based Meril Life Sciences has been manufacturing its Myval transcatheter heart valves for years, but the technology has not yet gained FDA approval. This latest head-to-head comparison included data from more than 1,000 TAVR patients.

READ MORE >
Meril Life Sciences, an India-based medical device company founded in 2006, developed the Myval TAVR valve. The Myval transcatheter heart valve (THV) is non-inferior to the Sapien 3 THV after one year, according to new transcatheter aortic valve replacement (TAVR) data published in The Lancet.
Share on Twitter Share on Facebook Share on Linkedin

Myval TAVR valve non-inferior to Sapien 3 after 1 year—pacemaker implants the biggest difference

Share on Twitter Share on Facebook Share on Linkedin
Meril Life Sciences, an India-based medical device company founded in 2006, developed the Myval TAVR valve. The Myval transcatheter heart valve (THV) is non-inferior to the Sapien 3 THV after one year, according to new transcatheter aortic valve replacement (TAVR) data published in The Lancet.
India-based Meril Life Sciences has been manufacturing its Myval transcatheter heart valves for years, but the technology has not yet gained FDA approval. This latest head-to-head comparison included data from more than 1,000 TAVR patients.
READ MORE >

AI-powered risk model evaluates long-term risk of coronary artery disease

The advanced machine learning model tracks more than 50 different factors to make its predictions. It has already been found to be more accurate than popular prediction methods for heart disease that are currently available. 

READ MORE >
artificial intelligence AI heart cardiology
Share on Twitter Share on Facebook Share on Linkedin

AI-powered risk model evaluates long-term risk of coronary artery disease

Share on Twitter Share on Facebook Share on Linkedin
artificial intelligence AI heart cardiology
The advanced machine learning model tracks more than 50 different factors to make its predictions. It has already been found to be more accurate than popular prediction methods for heart disease that are currently available. 
READ MORE >

In Other News

Disgruntled radiographer arrested after driving car through crowd of children

The tech is said to have been behind the wheel of a vehicle that drove into a group of second and third graders on their way home from school.

READ MORE >
police cop car siren
Share on Twitter Share on Facebook Share on Linkedin

Disgruntled radiographer arrested after driving car through crowd of children

Share on Twitter Share on Facebook Share on Linkedin
police cop car siren
The tech is said to have been behind the wheel of a vehicle that drove into a group of second and third graders on their way home from school.
READ MORE >

White House releases 2026 ‘skinny budget’ calling for $33B in cuts to HHS

The proposal would cut funds to the Centers for Disease Control and Prevention and the National Institutes of Health. However, no reduction was suggested for the Food and Drug Administration. 

READ MORE >
Share on Twitter Share on Facebook Share on Linkedin

White House releases 2026 ‘skinny budget’ calling for $33B in cuts to HHS

Share on Twitter Share on Facebook Share on Linkedin
The proposal would cut funds to the Centers for Disease Control and Prevention and the National Institutes of Health. However, no reduction was suggested for the Food and Drug Administration. 
READ MORE >

Innovate Healthcare thanks our partners for supporting our newsletters.
Sponsorship has no influence on editorial content.

Interested in reaching our audiences, contact our team

*|LIST:ADDRESSLINE|*

You received this email because you signed up for newsletters from Innovate Healthcare.
Change your preferences or unsubscribe here

Contact Us  |  Unsubscribe from all  |  Privacy Policy

© Innovate Healthcare, a TriMed Media brand
Innovate Healthcare

Recent Newsletters

Medtech giant makes big move | The world’s top hospitals for heart surgery | New CPT codes | PET vs. SPECT | TAVR tech recalled
AI is gaining ground, but clinicians run the show | Siemens Healthineers doubles down | Electrophysiologist compensation
News Alert: FDA shares warning about heart valve tech after patient death
Cardiologist pay & productivity are up | FDA clears PE thrombectomy devices | Cardiology tech in spotlight | Gore's new approval
Cardiology salaries on the rise | The climbing costs of care | M&A trends | Siemens Healthineers, J&J make big business moves
Major MRI trends | Blood thinner recalled | When to perform PCI before TAVR | How to build a CCTA program | Steroids & the heart
CMS boosts coverage for heart failure tech | FDA approves CardioMEMS updates | LVADs linked to strokes, other risks
Newsletter archive
  • Home
  • News
  • Article Archive
  • Custom Content
  • Webinars
  • Press Releases
  • Content Studio
  • Advertising
  • Submit Press Release
  • Contact Us
  • Terms of Use
  • Privacy Policy
  • Cardiovascular Business
  • HealthExec
  • Radiology Business
  • Press Releases
  • Submit Press Release
© 2026 Innovate Healthcare | All Rights Reserved. | Terms of Use | Privacy Policy
Design by Adaptive Theme
Trimed Popup